REG - Arecor Therapeutics - Director/PDMR Dealings

Arecor TherapeuticsAnnouncement

04/08/2022 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220804:nRSD9170Ua&default-theme=true

RNS Number : 9170U  Arecor Therapeutics PLC  04 August 2022

4 August 2022

Arecor Therapeutics plc

("Arecor" or the "Company" or the "Group")

Director/PDMR Dealings

and

Completion of the Acquisition of Tetris Pharma

Arecor Therapeutics plc (AIM: AREC), a globally focused
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that further to the Placing and acquisition of Tetris
Pharma, details of which were announced on 1 August 2022, pursuant to the
Placing, the following Directors subscribed for an aggregate amount of
£113,271 at the Placing Price of 300 pence per ordinary share.

Following General Admission today, the Placing and acquisition of Tetris
Pharma have now completed.

The following Directors interests in Ordinary Shares are as follows:

 Name                                      Placing Shares acquired  Resultant shareholding following Admission  % of the Enlarged Share Capital
 Sarah Howell (Chief Executive Officer)    6,666                    847,072.00                                  2.8%
 Susan Lowther (Chief Financial Officer)   3,334                    139,849.00                                  0.5%
 Andrew Richards (Chair)                   6,666                    223,834.00                                  0.7%
 Sam Fazeli (Non-Executive Director)       7,756                    115,708.00                                  0.4%
 Jeremy Morgan (Non-Executive Director)    6,666                    27,169.00                                   0.1%
 Christine Soden (Non-Executive Director)  6,667                    19,167.00                                   0.1%
 Total                                     37,755

 

The capitalised terms used in this announcement have the same meanings as in
the announcement published by the Company at 7.00 a.m. on 1 August 2022
unless otherwise stated.

 

For more information, please contact:

 

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com (mailto:info@arecor.com)

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray         Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         a)   Sarah Howell

                                                                   b)   Susan Lowther

                                                                   c)   Andrew Richards

                                                                   d)   Sam Fazeli

                                                                   e)   Jeremy Morgan

                                                                   f)    Christine Soden

 2    Reason for the notification

 a)   Position/status                                              a)   Chief Executive Officer

                                                                   b)   Chief Financial Officer

                                                                   c)   Chair

                                                                   d)   Non-executive Director

                                                                   e)   Non-executive Director

                                                                   f)    Non-executive Director

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Arecor Therapeutics plc

 b)   LEI                                                          98450093D12I3A8DDD58

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 1p each

      Identification code                                          ISIN: GB00BMWLM973

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)             Volume(s)
                                                                                     a)   300 pence       a)   6,666

                                                                                     b)   300 pence       b)   3,334

                                                                                     c)   300 pence       c)   6,666

                                                                                     d)   300 pence       d)   7,756

                                                                                     e)   300 pence       e)   6,666

                                                                                     f)    300 pence      f)    6,667

 d)   Aggregated information

      - Aggregated volume                                          37,755

      - Price                                                      300 pence

 e)   Date of the transaction                                      4 August 2022

 f)   Place of the transaction                                     XLON

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKQBPOBKKPFK